中国新药杂志

基于组蛋白去乙酰化酶设计的多靶点抗肿瘤药物研究进展

PDF下载

丁娇丽 ¹ , 张志鹏 ¹ , 刘婧 ² , 周维新 ¹ , 金一 ¹ , 谢赛赛 ¹

中国新药杂志 | 综述 2021,30(3): 236-245

收起

中国新药杂志 |综述 2021 , 30 (3) : 236 -245

基于组蛋白去乙酰化酶设计的多靶点抗肿瘤药物研究进展

全屏

丁娇丽¹, 张志鹏¹, 刘婧², 周维新¹, 金一¹, 谢赛赛¹

作者信息

¹江西中医药大学中药固体制剂制造技术国家工程研究中心，南昌　330004

²江西中医药大学药学院，南昌　330004

通讯作者:

谢赛赛，男，副教授，研究生导师，研究方向：药物合成化学。联系电话：（0791）87119623，E-mail：xiesaisainanchang@hotmail.com。

作者简介:

丁娇丽，女，硕士研究生，研究方向：药物合成化学。E-mail：3271103267@qq.com。

Research progress on design of multi-target anticancer drugs based on histone deacetylases

Jiao-li DING¹, Zhi-peng ZHANG¹, Jing LIU², Wei-xin ZHOU¹, Yi JIN¹, Sai-sai XIE¹

Affiliations

¹National Pharmaceutical Engineering Research Center for Solid Preparation in Chinese Herbal Medicine, Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, China

²School of Pharmacy, Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, China

出版时间: 2021-02-15

文章导航

摘要

收起

肿瘤的发生是一个多因子、多步骤的复杂过程。多靶点抗肿瘤药物能同时作用于肿瘤发生的多个疾病通路，比单靶点抗肿瘤药物有更好的治疗效果。研究显示，组蛋白去乙酰化酶（histone deacetylase，HDACs）在多种肿瘤细胞中过度表达，是肿瘤发生的关键靶点，因此以抑制HDACs为基础设计兼顾作用于其他靶点的多靶点抗肿瘤药物，成为重要的研究方向。目前已有5个HDAC抑制剂被批准上市用于治疗皮肤T细胞淋巴瘤、多发性骨髓瘤和外周T细胞淋巴瘤，还有十几个HDAC抑制剂正处于不同的临床研究阶段用于治疗各种癌症。基于此，本文综述了近年来此类多靶点分子的设计和生物活性研究，以期为进一步研发此类多靶点药物提供参考。

关键词

组蛋白去乙酰化酶抑制剂 / 多靶点 / 抗肿瘤药物 / 激酶 / 协同作用

Abstract

收起

The occurrence of tumor is a complicated process involving many factors and steps. It has been well validated that multi-target anticancer drugs that can simultaneously interact with two or more targets may offer greater therapeutic benefits than single target anticancer drugs. Studies indicate that HDACs are overexpressed in different human tumor cell lines, and have been identified as key targets of tumorigenesis. Therefore, design of multi-target anticancer drugs that can simultaneously act on HDACs and other targets has become an important research direction. To date, five HDAC inhibitors have been approved for the treatment of cancers including cutaneous T-cell lymphoma, multiple myeloma and peripheral T-cell lymphoma. There are several HDAC inhibitors at various stages of clinical trials against different cancers. Based on this, this paper reviews the design and biological activity of multi-target anticancer drugs based on the structures of HDAC inhibitors in recent years, aiming to provide reference for the further development of such multi-target molecules.

Key words

HDAC inhibitors / multi-target / antitumor drugs / kinase / synergistic effect

引用本文

丁娇丽, 张志鹏, 刘婧, 周维新, 金一, 谢赛赛. 基于组蛋白去乙酰化酶设计的多靶点抗肿瘤药物研究进展. 中国新药杂志, 2021 , 30 (3) : 236 -245 .

Jiao-li DING, Zhi-peng ZHANG, Jing LIU, Wei-xin ZHOU, Yi JIN, Sai-sai XIE. Research progress on design of multi-target anticancer drugs based on histone deacetylases[J]. Chinese Journal of New Drugs, 2021 , 30 (3) : 236 -245 .

基金

收起

国家自然科学基金资助项目(21807052)
江西省科技创新杰出青年人才培养计划(20192BCB23018)
江西省自然科学基金资助项目(20192ACBL21034)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

[1]

WEICHERT W. HDAC expression and clinical prognosis in human malignancies[J]. Cancer Lett, 2009, 280(2): 168-176.

[2]

SIMON F. The trouble with making combination drugs[J]. Nat Rev Drug Discov, 2006, 5(11): 881-882.

[3]

CAI X, ZHAI H, WANG J, et al. Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer[J]. J Med Chem, 2010, 53(5): 2000-2009.

[4]

郭政, 张庆伟, 张子学, 等. 苯甲酰胺类EGFR/HDAC双靶点抑制剂的合成及抗肿瘤活性(英文)[J]. 中国医药工业杂志, 2019(6): 609-617.

[5]

GRUNSTEIN M. Histone acetylation in chromatin structure and transcription[J]. Nature, 1997, 389(6649): 349-352.

[6]

MARMORSTEIN R, ROTH SY. Histone acetyltransferases: function, structure, and catalysis[J]. Curr Opin Genet Dev, 2001, 11(2): 155-161.

[7]

GLOZAK MA, SENGUPTA N, ZHANG XH, et al. Acetylation and deacetylation of non-histone proteins[J]. Gene, 2005, 363: 15-23.

[8]

MINAMIYA Y, ONO T, SAITO H, et al. Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung[J]. Lung Cancer, 2011, 74(2): 300-304.

[9]

SAKUMA T, UZAWA K, ONDA T, et al. Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma[J]. Int J Oncol, 2006, 29(1): 117-124.

[10]

STENZEL K, HAMACHER A, HANSEN FK, et al. Alkoxyurea-based histone deacetylase inhibitors increase cisplatin potency in chemoresistant cancer cell lines[J]. J Med Chem, 2017, 60(13): 5334-5348.

[11]

LU X, NING Z, LI Z, et al. Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China[J]. Intractable Rare Dis Res, 2016, 5(3): 185-191.

[12]

MARSON CM. Histone deacetylase inhibitors: design, structure-activity relationships and therapeutic implications for cancer[J]. Anticancer Agents Med Chem, 2009, 9(6): 661-692.

[13]

MCCORMACK E, HAALAND I, VENÅS G, et al. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia[J]. Leukemia, 2012, 26(5): 910-917.

[14]

HE S, DONG G, WU S, et al. Small molecules simultaneously inhibiting p53-murine double minute 2 (MDM2) interaction and histone deacetylases (HDACs): discovery of novel multitargeting antitumor agents[J]. J Med Chem, 2018, 61(16): 7245-7260.

[15]

MA VT, BOONSTRA PS, MENGHRAJANI K, et al. Treatment with JAK inhibitors in myelofibrosis patients nullifies the prognostic impact of unfavorable cytogenetics[J]. Clin Lymphoma Myeloma Leuk, 2018, 18(5): e201-e210.

[16]

HART S, GOH KC, NOVOTNY-DIERMAYR V, et al. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies[J]. Leukemia, 2011, 25(11): 1751-1759.

[17]

YANG EG, MUSTAFA N, TAN EC, et al. Design and synthesis of Janus kinase 2 (JAK2) and histone deacetlyase (HDAC) bispecific inhibitors based on pacritinib and evidence of dual pathway inhibition in hematological cell lines[J]. J Med Chem, 2016, 59(18): 8233-8262.

[18]

YAO LB, MUSTAFA N, TAN EC, et al. Design and synthesis of ligand efficient dual inhibitors of Janus kinase (JAK) and histone deacetylase (HDAC) based on ruxolitinib and vorinostat[J]. J Med Chem, 2017, 60(20): 8336-8357.

[19]

HUANG Y, DONG G, LI H, et al. Discovery of Janus kinase 2 (JAK2) and histone deacetylase (HDAC) dual inhibitors as a novel strategy for the combinational treatment of leukemia and invasive fungal infections[J]. J Med Chem, 2018, 61(14): 6056-6074.

[20]

HUANG JM, SHEARD MA, JI L, et al. Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53[J]. Mol Cancer Ther, 2010, 9(12): 3289-3301.

[21]

LI YT, LUO XH, GUO QX, et al. Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)-N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK_4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer[J]. J Med Chem, 2018, 61(7): 3166-3192.

[22]

SURAWEERA A, O'BYRNE KJ, RICHARD DJ. Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi[J]. Front Oncol, 2018, 8: 92.

[23]

CHEN Y, YUAN X, ZHANG W, et al. Discovery of novel dual histone deacetylase and mammalian target of rapamycin target inhibitors as a promising strategy for cancer therapy[J]. J Med Chem, 2019, 62(3): 1577-1592.

[24]

HEAVEY S, CUFFE S, FINN S, et al. In pursuit of synergy: an investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC[J]. Oncotarget, 2016, 7(48): 79526-79543.

[25]

LEONG S, MOSS RA, BOWLES DW, et al. A phase I dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with erlotinib in patients with advanced solid tumors[J]. Oncologist, 2017, 22(12): 1491-1499.

[26]

YOSHIOKA T, YOGOSAWA S, YAMADA T, et al. Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS[J]. Gynecol Oncol, 2013, 129(2): 425-432.

[27]

QIAN C, LAI CJ, BAO R, et al. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling[J]. Clin Cancer Res, 2012, 18(15): 4104-4113.

[28]

CHEN Y, WANG XY, XIANG W, et al. Development of purine-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities[J]. J Med Chem, 2016, 59(11): 5488-5504.

[29]

ZHANG K, LAI F, LIN S, et al. Design, synthesis, and biological evaluation of 4-methyl quinazoline derivatives as anticancer agents simultaneously targeting phosphoinositide 3-kinases and histone deacetylases[J]. J Med Chem, 2019, 62(15): 6992-7014.

[30]

CEA M, SONCINI D, FRUSCIONE F, et al. Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells[J]. PLoS One, 2011, 6(7): e22739.

[31]

DONG G, CHEN W, WANG X, et al. Small molecule inhibitors simultaneously targeting cancer metabolism and epigenetics: discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) and histone deacetylase (HDAC) dual inhibitors[J]. J Med Chem, 2017, 60(19): 7965-7983.

[32]

COMMANDER H, WHITESIDE G, PERRY C. Vandetanib: first global approval[J]. Drugs, 2011, 71(10): 1355-1365.

[33]

PENG FW, XUAN J, WU TT, et al. Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC[J]. Eur J Med Chem, 2016, 109: 1-12.

[34]

TAVALLAI S, HAMED HA, GRANT S, et al. Pazopanib and HDAC inhibitors interact to kill sarcoma cells[J]. Cancer Biol Ther, 2014, 15(5): 578-585.

[35]

ZANG J, LIANG XW, HUANG YX, et al. Discovery of novel pazopanib-based HDAC and VEGFR dual inhibitors targeting cancer epigenetics and angiogenesis simultaneously[J]. J Med Chem, 2018, 61(12): 5304-5322.

[36]

DUAN YC, MA YC, QIN WP, et al. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment[J]. Eur J Med Chem, 2017, 140: 392-402.

[37]

YAMASHITA M, TAHARA T, HAYAKAWA S, et al. Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-Targeted inhibitors[J]. Bioorg Med Chem, 2018, 26(8): 1920-1928.

[38]

LAMAA D, LIN HP, ZIG L, et al. Design and synthesis of tubulin and histone deacetylase inhibitor based on Iso-combretastatin A-4[J]. J Med Chem, 2018, 61(15): 6574-6591.

[39]

LU D, YAN J, WANG L, et al. Design, synthesis, and biological evaluation of the first c-met/HDAC inhibitors based on pyridazinone derivatives[J]. ACS Med Chem Lett, 2017, 8(8): 830-834.

[40]

SHIMIZU T, LORUSSO PM, PAPADOPOULOS KP, et al. Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors[J]. Clin Cancer Res, 2014, 20(19): 5032-5040.

[41]

朱玉垚, 王瑜, 马俊杰. 组蛋白去乙酰化酶抑制剂中锌离子结合基团的研究进展[J]. 中国新药杂志, 2020, 29(10): 1122-1130.

[42]

2021年第30卷第3期

PDF下载

引用本文

BibTeX

文章信息

首发时间：2026-10-29
出版时间：2021-02-15

补充材料

相关文章

文章信息

作者

出版历史

录用日期：2020-04-25

基金

国家自然科学基金资助项目(21807052)

江西省科技创新杰出青年人才培养计划(20192BCB23018)

江西省自然科学基金资助项目(20192ACBL21034)

作者信息

¹江西中医药大学中药固体制剂制造技术国家工程研究中心，南昌　330004

²江西中医药大学药学院，南昌　330004

通讯作者:

谢赛赛，男，副教授，研究生导师，研究方向：药物合成化学。联系电话：（0791）87119623，E-mail：xiesaisainanchang@hotmail.com。

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zgxyzz/CN/1322627038670864711

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT